Angiotensin (1-7) (Ang-(1-7), Angiotensin fragment 1-7) is a bioactive component of the renin-angiotensin system that is formed endogenously from either Ang I or Ang II. Angiotensin (1-7) is a canine ACE inhibitor with an IC50 of 0.65 μM and inhibits the activity mediated by myostatin through Mas receptor.
Angiotensin (1-7) prevents the decrease of the myotube diameter and MHC Levels Induced by myostatin in C2C12 cells. Angiotensin (1-7) decreases the myostatin-dependent increment of E3 ubiquitin ligases and ROS, the NF-κB signaling induced by myostatin, the myostatin-dependent activity through the mas receptor and Akt/PKB activity in C2C12 myotubes.[1]
Daily Angiotensin (1-7) administration significantly reduces colitis severity observable at both gross and histological levels in DSS treated mice. The anti-inflammatory effects of Angiotensin (1-7) treatment are associated with a reduction in the phosphorylated forms of p38 MAPK, ERK1/2 and Akt post DSS induction, the anti-inflammatory properties of Angiotensin (1-7) are in part mediated through reduction of Ang II levels.[3]
[1] Javier Aravena, et al. Int J Mol Sci. 2020 Feb 10;21(3):1167. [2] P Li, et al. Hypertension . 1997 Jan;29(1 Pt 2):394-400. [3] Maitham A Khajah, et al. PLoS One. 2016 Mar 10;11(3):e0150861.